Tirzepatide for weight loss: what TikTok gets right and wrong

What did @killer.b.stitches actually say?

Pretty straightforward stuff. She's three months into tirzepatide, down 28.2 pounds from a starting weight of 203 pounds, which puts her at 174.8. She also tracked body fat, dropping from 41.5% to 38.4%. She reported minimal side effects and one full week of zero movement on the scale at week 12. Her takeaway: "this is still probably the best thing I've ever done for myself."

There are no outrageous claims here. No promises to her audience, no dosing advice, no before-and-after photos with misleading lighting. This is someone tracking her own numbers and sharing them. That matters when we're evaluating what she actually said versus what people might infer.

Does the science back this up?

Yes, mostly. A 14% body weight reduction in three months is aggressive but not outside the range seen in clinical trials for tirzepatide. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants losing up to 20.9% of body weight over 72 weeks, with meaningful losses occurring in the first 12 weeks during dose escalation.

Her stall at week 12 is also completely consistent with the literature. Weight loss with GLP-1 and GIP/GLP-1 receptor agonists is not linear. Metabolic adaptation, dose titration plateaus, and water retention shifts all contribute to weeks where the scale doesn't move. Researchers have documented these plateaus extensively. A zero-change week after rapid early loss isn't failure. It's physiology doing what physiology does.

The body fat percentage drop she reported, from 41.5% to 38.4%, is plausible but harder to verify without knowing her measurement method. Consumer-grade bioimpedance scales have a margin of error of 3-8% (Dehghan and Merchant, 2008, Nutrition Journal), which means her body fat number should be read as a trend, not a precise figure.

What did they get wrong (or right)?

She got the big things right. Her weight loss rate is aggressive but documented in trial data. Her acknowledgment of a plateau week without catastrophizing it is actually good modeling for her audience. She didn't claim tirzepatide cures anything. She didn't recommend a dose. She kept this personal.

The one thing worth flagging isn't really wrong, it's just incomplete. Body fat percentage measured on a home scale is noisy data. A 3.1 percentage point drop sounds meaningful, but if the instrument has a 4-point error range, the actual change could be smaller or larger than reported. She's not lying, she just may be reading precision into a measurement that doesn't support it.

Also worth noting: 28 pounds in 90 days at her starting weight is fast. The SURMOUNT-1 data suggests this rate is achievable but typically seen during escalation phases. Whether that pace continues, slows, or stalls depends on factors she hasn't mentioned, including her dose, caloric intake, and activity level.

What should you actually know?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is not the same drug as semaglutide, and the two are not interchangeable. Tirzepatide's dual mechanism appears to produce stronger weight loss outcomes than GLP-1 agonism alone, which is why the SURMOUNT-1 results were striking when they published.

Results like hers are real. They are also not universal. The same SURMOUNT-1 trial showed a wide distribution of outcomes. Some participants lost significantly more. Some lost less. Starting weight, metabolic health, adherence, and individual response all shape what someone actually experiences.

A week of no loss is not a sign the medication stopped working. It is a normal feature of the weight loss process under any intervention, including GLP-1 therapy. If you're evaluating whether tirzepatide is appropriate for you, that conversation belongs with a licensed clinician who has access to your full health history, not a TikTok comment section.

The bottom line on this video

This is one of the more responsible GLP-1 progress videos out there. She tracked real numbers, acknowledged a stall without spinning it, and kept her claims personal rather than prescriptive. The body fat data has measurement caveats, but she's not selling anything. The weight loss figure is consistent with clinical data for tirzepatide at three months. Credit where it's due: she got this mostly right.